Transparency Market Research
This report studies the global market for companion diagnostics from two perspectives – companion diagnostics by indication and by geography. The market for companion diagnostics by indication includes sub-segments such as breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma and others (HIV, Thalassemia). By geography, the companion diagnostics market has been divided into four regions, namely, North America, Europe, Asia-Pacific and RoW. Market size and forecast for each segment and sub-segment has been provided for the period 2011 to 2019 in terms of USD million, with 2012 as the base year. The compounded annual growth rate (CAGR) for each market segment has been provided for the forecast period (2013 to 2019).
The report also contains a section on market overview which consists of a detailed qualitative analysis of various market dynamics, such as drivers, restraints and opportunities. A section on market attractiveness analysis and Porter’s five force analysis for the companion diagnostics market has also been included.
Market share analysis of the leading players operating in the companion diagnostics market, in terms of % share for the year 2012, has been presented in the competitive landscape. The report also includes the list of recommendations for new market entrants. Some of the key market players profiled in this report include Roche Holdings AG, Abbott Laboratories, Genomic Health, Inc., Qiagen N.V., Life Technologies Corporation, Agilent Technologies, Inc. and GE Healthcare, Ltd.
The global companion diagnostics market is segmented into the following categories:
Companion Diagnostics Market, by Indications
Companion Diagnostics Market, by Geography